Head and Neck Cancer (HNSCC)

HittPack™

A search of the latest news and medical research findings

October 5, 2011
Contents

I. Disease and Treatment Information in HNSCC ................................................................. 2

II. Recent News Articles in HNSCC ......................................................................................... 2
    Medscape Medical News (free password required) .............................................................. 2
    MedpageToday .................................................................................................................... 3
    Reuters Health .................................................................................................................... 4

III. Press Releases in HNSCC ................................................................................................. 4
    Eurekalert.org .................................................................................................................... 4
    Newswise.com .................................................................................................................... 8
    Google.com ........................................................................................................................ 13

IV. US Food and Drug Administration Info on HNSCC ......................................................... 14
    Drugs@FDA Database ........................................................................................................ 14
    2011 Advisory Committee Meetings .................................................................................. 17

V. Guidelines in HNSCC ....................................................................................................... 17
    National Guidelines Clearinghouse—Guidelines.gov ........................................................ 17
    National Comprehensive Cancer Network ....................................................................... 18
    American Society of Clinical Oncology ......................................................................... 18

VI. Conferences and Medical Associations for HNSCC ..................................................... 18
    Conferences ....................................................................................................................... 18
    Medical Associations ........................................................................................................ 19

VII. Key Opinion Leaders in HNSCC ................................................................................. 19

VIII. Clinical Trials in Progress in HNSCC ......................................................................... 21

IX. PubMed Search in HNSCC ............................................................................................ 41
    Randomized Controlled Trials .......................................................................................... 41
    Reviews .............................................................................................................................. 41
    Editorials ............................................................................................................................ 48
I. Disease and Treatment Information in HNSCC

- **National Cancer Institute** - General information about Head and Neck Cancer (HNSCC)

- **American Society of Clinical Oncology** - Head and Neck Cancer
  Oncologist-approved cancer information from the American Society of Clinical Oncology
  http://www.cancer.net/patient/Cancer+Types/Head+and+Neck+Cancer

- **MD Anderson Cancer Center** – HNSCC General Information

- **WebMD** – Head and Neck Cancer
  http://www.webmd.com/cancer/head-and-neck-cancers-including-eye-directory

- **emedicine.medscape.com** - HNSCC

II. Recent News Articles in HNSCC

**Medscape Medical News (free password required)**

http://www.medscape.com/; search term = head and neck; all results for the past 3 months.

- **SWIFT MRI Shows Preoperative Potential in Mandibular Cancer** ... [in] daily use. For application for mandibular invasion in head and neck cancer patients, our team is planning to design and construct a SWIFT ... News, Medscape Medical News, September 2011

- **Even With Head and Neck Cancer, It Still Pays to Quit Smoking**... previous smokers and non-smokers. "While a significant focus in head and neck cancer has been on human papillomavirus and tumor biomarkers, it is ... News, Reuters Health Information, September 2011

- **New Ultrasound Technique May Help Avoid Thyroid Nodule Biopsies** A novel imaging technique that quantifies the elastic properties of tissue can differentiate between benign thyroid nodules and papillary thyroid ... News, Reuters Health Information, September 2011

- **Cancer-Fighting Virus Shown to Target Tumors Alone**... virus" so far approved by a regulatory agency is for treatment of head and neck cancer in China. In a study published in the journal Nature on Wednesday, ... News, Reuters Health Information, August 2011

- **SLNB 'Should Be Performed' for Melanoma of Head and Neck**... assert the prognostic value of the procedure in patients with head and neck cancer. Led by Audrey B. Erman, MD, the study authors conducted a chart ... News, Medscape Medical News, August 2011
• **Transthoracic or Transhiatal Surgery Equivalent for Esophagectomy** Five-year survival rates appear to be similar whether esophagectomy is done via thoracotomy or through the esophageal hiatus, according to a recent ... News, Reuters Health Information, August 2011

• **Clearer Guidelines Needed for RAI in Thyroid Cancer** Hospitals vary widely in the use of radioactive iodine, and clearer guidelines are needed to prevent both over- and undertreatment. News, Medscape Medical News, August 2011

• **Iodine Radioisotope Effective for Bone Mets From Thyroid Cancer** When differentiated thyroid cancer has spread to bone, iodine-131 can help stabilize the disease and significantly reduce pain, a Chinese team reports. News, Reuters Health Information, August 2011

• **Induction Effective in Locally Advanced Head and Neck CA**... regimen for nearly half the patients who presented with locally advanced **head and neck** squamous cell carcinoma (**HNSCC**) in a recent phase II trial. News, Reuters Health Information, August 2011

• **Ethanol Injections Control Thyroid CA Lymph Node Mets** Ultrasound-guided ethanol injections appear to control metastatic cervical lymph nodes in patients with papillary thyroid carcinoma, according to ... News, Reuters Health Information, July 2011

---

**MedpageToday**

http://www.medpagetoday.com/; search term = “head and neck”; all results for the past 3 months.

**Sentinel Nodes Reliable in Head and Neck Melanoma**

8/9/2011

Sentinel lymph node biopsy for head and neck melanomas appears both prognostic and safe despite debate on both counts, researchers argued.

---

**Cancer Risk Rises With Early Morning Smoke**

8/8/2011

A cigarette first thing in the morning may light up the risk of lung and head and neck cancers, according to case-control study findings.

---

**Chemoradiation of Modest Benefit in Recurrent HNC**

6/13/2011

For some patients with recurrent head and neck cancer, chemotherapy combined with re-irradiation of the tumor site offers a small but real chance of a cure, researchers said.
**Reuters Health**

http://www.reuters.com; search terms = HNSCC, “head and neck cancer”; all results for the past 3 months.

Amgen Dahanca 10 study results presented at ECCO annual meeting ...

... The study investigators completed their analysis of the data in July 2007 and have concluded that patients with primary HNSCC who were treated with Aranesp had ...

Tue Sep 25, 2007 6:43am EDT

CORRECTED - Cancer-fighting virus shown to target tumors alone

... OncoVex. But the only "oncolytic virus" so far approved by a regulatory agency is for treatment of head and neck cancer in China. ...

Thu Sep 1, 2011 9:04am EDT

**III. Press Releases in HNSCC**

Eurekalert.org

www.eurekalert.org; search terms = HNSCC, “head and neck cancer”; 15 results.

Genetics, lifestyle provide clues to racial differences in head and neck cancer

... and neck squamous cell carcinoma (HNSCC) and have a worse five ... group of 673 patients with HNSCC. Most notably, 42 percent of ... local host defense against tumors in HNSCC. "Understanding ...


Primary component in turmeric kicks off cancer-killing mechanisms in human saliva

... that drives the growth of head and neck cancer, according to ... curcumin suppressed the growth of head and neck cancer, first in ... found that the curcumin suppressed head and neck cancer growth by ...

Convergence in head and neck cancer

... Convergence in head and neck cancer ... genetic abnormalities previously suspected in head and neck cancer, including defects ... adds a new dimension to head and neck cancer biology that ...

Certain head and neck cancer patients benefit from second round of treatment

... Certain head and neck cancer patients benefit ... cure in select patients with head and neck cancer. Published early ... help guide treatment decisions for head and neck cancer patients. ...

Curcumin compound improves effectiveness of head and neck cancer treatment, U-M study finds

... Curcumin compound improves effectiveness of head and neck cancer treatment, U ... Mich. — A primary reason that head and neck cancer treatments fail ... based compound, called FLLL32, to head and neck cancer cell lines ...

Low-dose sorafenib may improve therapy for head and neck cancer

... sorafenib may improve therapy for head and neck cancer ... now often used to treat head and neck cancer might significantly ... 49,200 new cases of head and neck cancer are expected ...


FATE results prove to be useful in end-of-life care

... improvements in the treatment of head and neck cancer, there is ... end of life care for head and neck cancer patients, according ... end-of-life care to head and neck cancer patients. ... http://www.eurekalert.org/pub_releases/2011-05/aaoo-frp042211.php- 8.6KB - Public Press Releases

Combining CT, FDG-PET provides more accurate treatments for head and neck cancer patients

... provides more accurate treatments for head and neck cancer patients ... potentially different treatment options in head and neck cancer patients compared ... determining tumor delineation before deciding head and neck cancer treatment—typically ... http://www.eurekalert.org/pub_releases/2011-04/asfr-ccf042811.php- 7.4KB - Public Press Releases

Stress and depression are associated with shorter survival in head and neck cancer patients

... associated with shorter survival in head and neck cancer patients ... shorter disease-free survival in head and neck cancer patients. "... aggressiveness and poorer prognosis in head and neck cancer patients, certainly ... http://www.eurekalert.org/pub_releases/2011-04/fccc-sad042011.php- 10.2KB - Public Press Releases

AACR awards AACR-Thomas J. Bardos Science Education Award for Undergraduate Students

... role in laryngeal carcinogenesis among Puerto Ricans Abstract #3200. HPV status influences the survival of HNSCC patients: A consideration for the TNM staging system Allison Gomez, University of California San ... http://www.eurekalert.org/pub_releases/2011-03/aafc-
**BNCT, a new-generation radiation treatment, is effective in advanced head and neck cancer**

Treatment, is effective in advanced head and neck cancer... the treatment of locally recurrent head and neck cancer have been... majority of whom had recurred head and neck cancer or malignant...


---

**New way to identify patients at risk of dysphagia after head and neck cancer treatment**

... European Society for Medical Oncology New way to identify patients at risk of dysphagia after head and neck cancer treatment Phase III results At the 3rd International Conference on innovative...


---

**HIV-positive head and neck cancer patients benefit from radiation therapy**

... HIV-positive head and neck cancer patients benefit... January 18, 2011 – HIV-positive head and neck cancer patients respond... a current standard treatment for head and neck cancer, but there...


---

**Intensity-modulated radiotherapy protects saliva function and improves quality of life for...**

... cell carcinoma of the head and neck (HNSCC), the most common type of head and... 2003 and December 2007, 94 patients with HNSCC were enrolled from six radiotherapy centres...
3-drug combination shows long-lasting survival benefit in head and neck cancer patients

... long-lasting survival benefit in head and neck cancer patients
... term survival of patients with head and neck cancer, reducing the ... help patients with locally advanced head and neck cancer live longer ...

Newswise.com

www.newswise.com; search term = head and neck cancer, sorted by date. Results 1 through 2 of 50

Genetics, Lifestyle Provide Clues to Racial Differences in Head & Neck Cancer

Henry Ford Health System

2011-09-14

Why are African Americans more likely than Caucasians to be not only diagnosed with head and neck cancer, but also die from the disease? While the answer isn’t a simple one, differences in lifestyle, access to care and tumor genetics may, in part, be to blame, according to a new study from Henry Ford Hospital.

Gender, Insurance Type Tied to HPV Infection in Laryngeal Cancer Patients

Henry Ford Health System

2011-09-14

Researchers at Henry Ford Hospital in Detroit say HPV is much more likely to be found in tumors of laryngeal (voice box) cancer patients who are male and those with private health insurance, a finding that could impact head and neck cancer screening and treatment.

Primary Component of Turmeric Kicks Off Cancer-Killing Mechanisms in Human Saliva

University of California, Los Angeles (UCLA), Health Sciences
Curcumin, the main component in the spice turmeric, suppresses a cell signaling pathway that drives the growth of head and neck cancer, according to a pilot study using human saliva by researchers at UCLA’s Jonsson Comprehensive Cancer Center.

**Study Links 23 MicroRNAs to Laryngeal Cancer**

**Henry Ford Health System**

2011-09-13

A Henry Ford Hospital study has identified 23 microRNAs for laryngeal cancer, 15 of which had yet to be reported in head and neck cancer. The researchers say the discovery could yield new insight into what causes certain cells to grow and become cancerous tumors in the voice box.

**Sentinel Node Biopsy Safe, Effective in Head and Neck Melanomas, U-M Study Finds**

**University of Michigan Health System**

2011-08-05

A common technique for determining whether melanoma has spread can be used safely and effectively even in tumors from the head and neck area, according to a new study from the University of Michigan Comprehensive Cancer Center.

**Convergence in Head and Neck Cancer --Centers Collaborate to Reveal Unexpected Genetic Mutations**

**Johns Hopkins Medicine**

2011-07-28

Baltimore, MD; Boston and Cambridge MA; Pittsburgh, PA; and Houston, TX. Thurs. July 28, 2011 -- Powerful new technologies that zoom in on the connections between human genes and diseases have illuminated the landscape of cancer, singling out changes in tumor DNA that drive the development of certain types of malignancies such as melanoma or ovarian cancer.

**NYU Cancer Institute Experts Present at 47th American Society of Clinical Oncology 2011 Annual Meeting**

**New York University Langone Medical Center**

2011-06-06
Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL. The conference was held June 3-7, 2011 and scientists from the NYU Cancer Institute discussed various new research findings in melanoma, breast cancer, head & neck cancer, prostate cancer and pediatric oncology.

**Curcumin Compound Improves Effectiveness of Head and Neck Cancer Treatment**

**University of Michigan Health System**

2011-05-19

A primary reason that head and neck cancer treatments fail is the tumor cells become resistant to chemotherapy drugs. Now, researchers at the University of Michigan Comprehensive Cancer Center have found that a compound derived from the Indian spice curcumin can help cells overcome that resistance.

**Combining CT, FDG-PET Provides More Accurate, Individualized Treatments for Head and Neck Cancer Patients**

**American Society for Radiation Oncology (ASTRO)**

2011-04-29

Combining computerized tomography (CT) with fluorodeoxyglucose positron emission tomography (FDG-PET) images results in significantly more defined tumor outlines and potentially different treatment options in head and neck cancer patients compared to using CT alone, according to research presented today, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North America (RSNA).

**Tulane Doctor Performs New Robotic Throat Cancer Surgery**

**Tulane University**

2011-02-08

New robotic surgery for throat cancer has fewer complications, faster recovery time.

**Researchers Identify a Key Enzyme That Affects Radiation Response in Head and Neck Cancer Patients**

**University Health Network (UHN)**

2011-01-26
Cancer researchers at Princess Margaret Hospital (PMH) have discovered that targeting an enzyme called Uroporphyrinogen Decarboxylase (UROD) can sensitize diseased tissue to radiation and chemotherapy, which could mean fewer side effects for individuals with head and neck cancer.

**Estrogen May Help Precancerous Cells Spread in Oral Cavity**

**American Association for Cancer Research (AACR)**

2011-01-04

1) Head and neck cancer accounts for 650,000 new cancer cases each year; 2) Data provide insight into novel mechanisms underlying head and neck cancer; 3) Potential new targets for chemoprevention identified.

**Pain, Dry Mouth Affect Head/Neck Cancer Patients’ Sleep Quality**

**University of Michigan Health System**

2010-07-12

Head and neck cancer patients who reported poor sleep quality one year after diagnosis had more symptoms of chronic pain and complaints of dry mouth related to radiation treatments, according to a recent study from the University of Michigan Comprehensive Cancer Center.

**Coffee May Protect Against Head and Neck Cancers**

**American Association for Cancer Research (AACR)**

2010-06-22

1) Caffeinated coffee protected against oral cavity, pharyngeal cancers; 2) Regular coffee drinkers had a 39 percent decreased risk of cancer.

**Study Achieves Reduced Side Effects in Head and Neck Cancer Treatment**

**University of Michigan Health System**

2010-05-10

Researchers at the University of Michigan Comprehensive Cancer Center have applied advanced radiation techniques for head and neck cancer to avoid treating critical structures that affect swallowing and eating. A new study shows these principles and techniques treated the cancer effectively while greatly reducing long-term swallowing complications.

**Immune Cells Predict Success of Head and Neck Cancer Treatment**

**University of Michigan Health System**
Levels of a key type of immune cell are higher in head and neck cancer patients whose tumors are linked to the human papillomavirus, or HPV, according to researchers at the University of Michigan Comprehensive Cancer Center.

**Accelerated Radiation Therapy Reduces Toxicity in Patients with Advanced Head and Neck Cancers**

**American Society for Radiation Oncology (ASTRO)**

2010-02-25

Using an accelerated, shorter course of radiation therapy for patients with advanced head and neck cancer allows doctors to reduce the amount of chemotherapy, thus reducing toxicity, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

**Proton Beam Therapy Shows Encouraging Long-term Outcome for Patients with Locally Advanced Sinonasal Cancers**

**American Society for Radiation Oncology (ASTRO)**

2010-02-25

Proton beam radiation therapy shows encouraging results for patients with locally advanced sinonasal malignancies, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

**Larynx Preservation Treatments Result in Low Instance of Severe Voice Disability, Nutritional Dysfunction**

**American Society for Radiation Oncology (ASTRO)**

2010-02-25

Head and neck cancer patients receiving induction chemotherapy followed by radiation to preserve their larynx have a low-risk of severe voice disability and almost half experienced no eating or swallowing problems, according to a first of its kind study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

**Pretreatment SUV Associated with Head and Neck Cancer Treatment Outcomes, May Help Decide Treatment Plans**

**American Society for Radiation Oncology (ASTRO)**

2010-02-25
The maximal standardized uptake value (called SUVmax) measured from FDG PET readings taken from the primary tumor in head and neck squamous cell carcinoma patients before treatment is a strong predictor of disease-specific survival, overall survival and disease-free survival, while pretreatment SUVmax for lymphodenopathy is strongly associated with distant metastasis, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

Google.com

Search term = “head and neck cancer press releases”. First 10 results returned

1. Centers map head and neck cancer genome - National Cancer ...
   www.cancer.gov/newscenter/pressreleases/.../...
   Jul 29, 2011 - Several major biomedical centers have collaborated to shine a light on head and neck squamous cell cancer. Their large-scale analysis has revealed a ...

2. Head and neck cancer patients benefit from 2 rounds of chemo ...
   Jun 13, 2011 - A new study from the University of Chicago has determined predictors that ...

   www.hopkinsmedicine.org › ... › For the Media › Current News Releases
   Jul 28, 2011 - Powerful new technologies that zoom in on the connections between human genes and diseases have illuminated the landscape of cancer, singling out ...

4. Wiley: Certain Head and Neck Cancer Patients Benefit from Second ...
   Jun 13, 2011 - Cover image for product CNCR. Cancer. More Press Releases related to this journal ...
   Radiation is often used to treat patients with head and neck cancer. ...

5. Research and Markets: Global Head and Neck Cancer Drug ...
   www.pharmiweb.com/pressreleases/pressrel.asp?... - United Kingdom
   Sep 29, 2011 - Research and Markets (http://www.researchandmarkets.com/research/916e85/global_head_and_ne) has announced the addition of the.
6. **First Genetic Variations Pinpointed in Head and Neck Cancer - MD ...**

www.mdanderson.org › Newsroom › MD Anderson News Releases

Jul 28, 2011 - The first comprehensive studies of genetic variation in head and neck squamous cell cancers have uncovered mutations that may help refine treatment for ...

7. **Polymeric Nanoparticles Attack Head and Neck Cancer**

www.nanotech-now.com › Press

Jul 21, 2011 - Head and neck cancer, the sixth most common cancer in the world, has ... Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely ...

8. **Convergence in Head and Neck Cancer: Centers Collaborate to ...**

www.upmc.com/MediaRelations/NewsReleases/.../Convergence-in-He...

Jul 28, 2011 - Collapse Media Relations ... News Release Search ... “This adds a new dimension to head and neck cancer biology that was not on anyone's radar screen ...

9. **Genetics, lifestyle provide clues to racial differences in head and neck**


Sep 14, 2011 - Why are African Americans more likely than Caucasians to be not only diagnosed with head and neck cancer, but also ... Public release date: 14-Sep-2011 ... 52140 news cases of head and neck cancer will be diagnosed, and roughly 11460 ...

10. **Collaboration reveals gene mutation link to head and neck cancer ...**

info.cancerresearchuk.org › ... › News articles

Jul 29, 2011 - Search News and Press releases ... Press Office. News provided by Press Association ... A gene mutation affecting head and neck cancer has been discovered ...

**IV. US Food and Drug Administration Info on HNSCC**

**Drugs@FDA Database**

Original New Drug Approvals (NDAs and BLAs) by Month; last 3 months listed


September 2011
<table>
<thead>
<tr>
<th>Drug Name and FDA Appl. #</th>
<th>Active Ingredients</th>
<th>NDA Chem. Type *</th>
<th>Review Classification **</th>
<th>Company</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>PUR-WASH (NDA # 022305)</td>
<td>PURIFIED WATER</td>
<td>5</td>
<td>5</td>
<td>NIAGARA PHARMA INC</td>
<td>09/01/2011</td>
</tr>
<tr>
<td>LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE (NDA # 202171)</td>
<td>LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE</td>
<td>4</td>
<td>5</td>
<td>MATRIX LABS LTD</td>
<td>09/08/2011</td>
</tr>
<tr>
<td>LAMIVUDINE; ZIDOVUDINE (NDA # 201151)</td>
<td>LAMIVUDINE; ZIDOVUDINE</td>
<td></td>
<td></td>
<td>CIPLA LIMITED</td>
<td>09/22/2011</td>
</tr>
<tr>
<td>LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE (NDA # 202171)</td>
<td>MEMANTINE HYDROCHLORIDE</td>
<td></td>
<td></td>
<td>TORRENT</td>
<td>09/27/2011</td>
</tr>
<tr>
<td>CLOBETASOL PROPIONATE (NDA # 201402)</td>
<td>CLOBETASOL PROPIONATE</td>
<td></td>
<td></td>
<td>PERRIGO ISRAEL</td>
<td>09/27/2011</td>
</tr>
</tbody>
</table>

August 2011

<table>
<thead>
<tr>
<th>Drug Name and FDA Appl. #</th>
<th>Active Ingredients</th>
<th>NDA Chem. Type *</th>
<th>Review Classification **</th>
<th>Company</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEMCITABINE (NDA # 200795)</td>
<td>GEMCITABINE HYDROCHLORIDE</td>
<td>3</td>
<td>S</td>
<td>HOSPIRA INC</td>
<td>08/04/2011</td>
</tr>
<tr>
<td>ROSUVASTATIN ZINC</td>
<td>ROSUVASTATIN ZINC</td>
<td>2</td>
<td>S</td>
<td>WATSON</td>
<td>08/04/2011</td>
</tr>
</tbody>
</table>
### Head and Neck Cancer HittPack™

<table>
<thead>
<tr>
<th>Drug Name and FDA Appl. #</th>
<th>Active Ingredients</th>
<th>NDA Chem. Type *</th>
<th>Review Classification **</th>
<th>Company</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>COMPLERA (NDA # 202123)</td>
<td>EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE</td>
<td>4</td>
<td>P</td>
<td>GILEAD SCIENCES INC</td>
<td>08/10/2011</td>
</tr>
<tr>
<td>ZELBORAF (NDA # 202429)</td>
<td>VEMURAFENIB</td>
<td>1</td>
<td>P</td>
<td>HOFFMAN LA ROCHE</td>
<td>08/17/2011</td>
</tr>
<tr>
<td>ADCETRIS (BLA # 125388)</td>
<td>BRENTUXIMAB VEDOTIN</td>
<td></td>
<td></td>
<td>SEATTLE GENETICS</td>
<td>08/19/2011</td>
</tr>
<tr>
<td>ADCETRIS (BLA # 125399)</td>
<td>BRENTUXIMAB VEDOTIN</td>
<td></td>
<td></td>
<td>SEATTLE GENETICS</td>
<td>08/19/2011</td>
</tr>
<tr>
<td>FIRAZYR (NDA # 022150)</td>
<td>ICATIBANT ACETATE</td>
<td>1</td>
<td>P</td>
<td>SHIRE ORPHAN THERAP</td>
<td>08/25/2011</td>
</tr>
<tr>
<td>NUCYNTA ER (NDA # 200533)</td>
<td>TAPENTADOL HYDROCHLORIDE</td>
<td>3</td>
<td>S</td>
<td>ORTHO MCNEIL JANSSEN</td>
<td>08/25/2011</td>
</tr>
<tr>
<td>XALKORI (NDA # 202570)</td>
<td>CRIZOTINIB</td>
<td>1</td>
<td>P</td>
<td>PFIZER</td>
<td>08/26/2011</td>
</tr>
</tbody>
</table>

### July 2011

<table>
<thead>
<tr>
<th>Drug Name and FDA Appl. #</th>
<th>Active Ingredients</th>
<th>NDA Chem. Type *</th>
<th>Review Classification **</th>
<th>Company</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARCAPTA NEOHALER (NDA # 022383)</td>
<td>INDACATEROL MALEATE</td>
<td>1</td>
<td>S</td>
<td>NOVARTIS</td>
<td>07/01/2011</td>
</tr>
<tr>
<td>XARELTO</td>
<td>RIVAROXABAN</td>
<td>1</td>
<td>S</td>
<td>JOHNSON AND</td>
<td>07/01/2011</td>
</tr>
</tbody>
</table>
**V. Guidelines in HNSCC**

**National Guidelines Clearinghouse--Guidelines.gov**

www.guidelines.gov; Search criteria = “HNSCC” all years, sorted by relevance, all results listed
1. **Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer: guideline recommendations.** 2009 May 15. NGC:007390
   Program in Evidence-based Care - State/Local Government Agency [Non-U.S.].
   View all guidelines by the developer(s)

2. **ACR Appropriateness Criteria® retreatment of recurrent head and neck cancer after prior definitive radiation.** 2010. NGC:007942
   American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)

3. **ACR Appropriateness Criteria® local-regional therapy for resectable oropharyngeal squamous cell carcinomas.** 2010. NGC:007941
   American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)

---

**National Comprehensive Cancer Network**

Free password required

**www.nccn.org**

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) in Head and Neck Cancers


**American Society of Clinical Oncology**

**www.asco.org**

American Society of Clinical Oncology: Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer

http://www.asco.org/ASCOv2/Practice+%26+Guidelines/Guidelines/Clinical+Practice+Guidelines/Head+and+Neck+Cancer

---

**VI. Conferences and Medical Associations for HNSCC**

**Conferences**
VII. Key Opinion Leaders in HNSCC

A listing of key opinion leaders (KOLs) in HNSCC who have participated in recent CME activities available online. Where possible, the sponsor information has been listed.

- **Marshall R. Posner, MD**, Associate Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Medical Director, Head and Neck Oncology Program, Dana-Farber Cancer Institute, Boston, Massachusetts. Received honoraria from: EMD Serono, Inc.; Sanofi-Aventis. Received grants for clinical research from: Abraxis Oncology; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Genentech, Inc.; ImClone Systems Incorporated; National Cancer Institute; National Institute of Allergy and Infectious Diseases; OSI Pharmaceuticals, Inc.; Sanofi-Aventis. Served as an advisor or consultant for: Amgen Inc.; BioVex Inc; Bristol-Myers Squibb Company; EMD Serono, Inc.; GlaxoSmithKline; ImClone Systems Incorporated; National Cancer Institute; Novartis Pharmaceuticals Corporation; OXiGENE, Inc.; Promedior, Inc.; sanofi-aventis; The DNA Repair Company

- **Désirée Lie, MD, MSED**, Clinical Professor, Family Medicine, University of California, Irvine, Orange, California; Director of Research and Patient Development, Family Medicine, University of California, Irvine, Medical Center, Rossmoor, California. Served as a nonproduct speaker for: “Topics in Health” for Merck Speaker Services.
• **Charles P. Vega, MD, FAAFP**, Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, FAAFP, has disclosed no relevant financial relationships.

• **Corey J. Langer, MD, FACP**, Professor, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania; Director, Thoracic Oncology, Hospital of the University of Pennsylvania/Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania. Received grants for clinical research from: Bristol-Myers Squibb Company; ImClone Systems Incorporated; Pfizer Inc.; Lilly Research Laboratories; Schering-Plough Research Institute; sanofi-aventis; Amgen Inc.; Cell Therapeutics, Inc.; Ortho Biotech Products, L.P.; Celgene Corporation; Vertex Pharmaceuticals Incorporated; Genentech, Inc.; OSI Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Active Biotech; MedImmune Inc. (absorbed by AstraZeneca Pharmaceuticals LP 2008). Served as an advisor or consultant for: Bristol-Myers Squibb Company; ImClone Systems Incorporated; sanofi-aventis; Pfizer Inc.; IntraBiotics Pharmaceuticals, Inc.; GlaxoSmithKline; Pharmacyclics, Inc.; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Genentech, Inc.; Savient Pharmaceuticals, Inc.; Bayer/Onyx; Abraxis Oncology; Abbott Laboratories. Other: speaker’s bureau: Bristol-Myers Squibb Company; sanofi-aventis; Lilly Research Laboratories; Ortho Biotech Products, L.P.; Genentech, Inc.; OSI Pharmaceuticals, Inc.

• **Maura L. Gillison, MD, PhD**, Professor of Medicine, Epidemiology and Otolaryngology, Jeg Coughlin Chair of Cancer Research, The Ohio State University, Columbus, Ohio. Disclosure: Maura L. Gillison, MD, PhD, has disclosed no relevant financial relationships.

• **Rodrigo Bayon, MD**, Resident Physician, Department of Otolaryngology-Head & Neck Surgery, Northwestern University Feinberg School of Medicine. Disclosure: Nothing to disclose.

• **Bruce Brockstein, MD**, Division of Hematology/Oncology, Evanston Northwestern Healthcare, Evanston, Illinois; Department of Medicine, Northwestern University, Feinberg School of Medicine, Evanston, Illinois. Bruce Brockstein, MD, has disclosed that he is a consultant for and serves on the speaker’s bureau for Pfizer and Novartis.

• **Matthew G. Fury, MD, PhD**, Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. Participated in funded or unfunded research on a technology, process, or product development for: Novartis Pharmaceuticals Corporation; Genentech Inc.; Bristol-Myers Squibb Company. Served as an advisory board member, speakers bureau member, expert witness, or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.

• **David G. Pfister, MD**, Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. Participated in funded or unfunded research on a technology, process, or product development for: Novartis Pharmaceuticals Corporation; ImClone

• **Mark Agulnik, MD**, Division of Hematology/Oncology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Evanston, Illinois. Disclosure: Mark Agulnik, MD, has disclosed that he has received honoraria as a consultant for Bristol-Myers Squibb and ImClone.
## VIII. Clinical Trials in Progress in HNSCC

**Clinical trials.gov**

*Search criteria - head and neck | Open Studies | Exclude Unknown | Phase III, IV*

100 of 118 studies listed

<table>
<thead>
<tr>
<th>Rank</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><strong>Stereotactic Body Radiotherapy for Head and Neck Tumors</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Conditions:</strong> Squamous Cell Carcinoma of the Head and Neck; Nasopharyngeal Carcinoma; Salivary Gland Cancer; Head and Neck Sarcoma; Paraganglioma of Head and Neck; Chordoma of Head and Neck; Chondrosarcoma of Head and Neck</td>
</tr>
<tr>
<td></td>
<td><strong>Interventions:</strong> Radiation: stereotactic body radiotherapy; Radiation: Stereotactic body radiotherapy</td>
</tr>
<tr>
<td>2</td>
<td><strong>The Use of Prostaglandin E1 in Head and Neck Microsurgery</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Conditions:</strong> Microsurgery; Head and Neck; Prostaglandin E1; Thrombosis; Complications</td>
</tr>
<tr>
<td></td>
<td><strong>Interventions:</strong> Drug: Prostaglandin E1; Other: Saline</td>
</tr>
<tr>
<td>3</td>
<td><strong>Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective?</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Conditions:</strong> Pain; Cancer of Head and Neck</td>
</tr>
<tr>
<td></td>
<td><strong>Interventions:</strong> Drug: fentanyl; Drug: methadone</td>
</tr>
<tr>
<td>4</td>
<td><strong>Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Condition:</strong> Head and Neck Cancer</td>
</tr>
</tbody>
</table>
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy

5 Phase III of Unilateral Neck Irradiation With Amifostine in Patients With SCC of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Radiation: amifostine plus radiation therapy (amifostine arm); Radiation: definitive external beam radiation in the ipsilateral neck

6 Dose Reduced Radiotherapy (63.3 Gy) With Paclitaxel/Cisplatin Versus Standard Radiotherapy (70.2 Gy) With 5-Fluorouracil/Cisplatin in Locally Advanced Head and Neck Cancer (Stages III and IV A-B)
Condition: Locally Advanced Head and Neck Cancer Stages III and IV A-B
Interventions: Drug: Paclitaxel/Cisplatin; Radiation: Reduced RT; Drug: 5-FU/Cisplatin; Radiation: Standard RT

7 Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck
Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: AFATINIB; Drug: Placebo of AFATINIB

8 TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.
Condition: Head and Neck Cancer
Interventions: Other: TPF, radiotherapy and cisplatin.; Other: TPF, radiotherapy and cetuximab

9 Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
Conditions: Cancer of the Head and Neck; Neoplasms,
10 DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC

Condition: Cancer of the Head and Neck
Interventions: Radiation: Radiotherapy; Drug: Zalutumumab

11 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil

12 Effects of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer

Conditions: Head and Neck Cancer; Stage I Hypopharyngeal Cancer; Stage I Laryngeal Cancer; Stage I Oropharyngeal Cancer; Stage II Hypopharyngeal Cancer; Stage II Laryngeal Cancer; Stage II Oropharyngeal Cancer; Stage III Hypopharyngeal Cancer; Stage III Laryngeal Cancer; Stage III Oropharyngeal Cancer; Stage IV Hypopharyngeal Cancer; Stage IV Laryngeal Cancer; Stage IV Oropharyngeal Cancer

Interventions: Behavioral: exercise intervention; Other: questionnaire administration; Procedure: quality-of-life assessment

13 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: intensity-modulated radiation therapy

14 Radiation Therapy CDDP With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer

Condition: Head and Neck Cancer

Interventions: Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy

15 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer

Condition: Head and Neck Cancer

Interventions: Procedure: computed tomography; Procedure: positron emission tomography; Procedure: therapeutic conventional surgery

16 Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Condition: LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Interventions: Other: RTX + CDDP/5-FU; Other: NO INDUCTION CHT + ( RTX + CETUXIMAB); Other: INDUCTION CHT + ( RTX + CDDP/5-FU); Other: INDUCTION CHT + ( RTX +CETUXIMAB)

17 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients

Condition: Oral Mucositis

Interventions: Device: MuGard; Device: Control Rinse
### 18 Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer

**Conditions:**
- Head and Neck Cancer
- Long-term Effects of Cancer Treatment
- Oral Complications of Radiation Therapy
- Radiation Toxicity
- Xerostomia

**Interventions:**
- Procedure: acupuncture therapy
- Procedure: sham intervention
- Procedure: standard follow-up care

### 19 Randomised Study of Mucositis Prevention After Radiochemotherapy Treatment for Head and Neck Cancer

**Conditions:**
- Severe Acute Mucositis
- Head and Neck Cancer

**Interventions:**
- Dietary Supplement: Oral Impact
- Dietary Supplement: Placebo

### 20 Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

**Condition:**
- Carcinoma, Squamous Cell of the Head and Neck

**Interventions:**
- Biological: REOLYSIN
- Drug: Carboplatin
- Drug: Paclitaxel
- Drug: Placebo

### 21 LUX-Head&Neck 2. Afatinib (BIBW 2992) Versus Placebo After Chemo-radiotherapy in Patients With Head and Neck Cancer

**Condition:**
- Head and Neck Neoplasms

**Interventions:**
- Drug: Placebo
- Drug: Afatinib

### 22 LUX-Head&Neck 1. Afatinib (BIBW2992) Versus Methotrexate in Recurrent and/or Metastatic (R/M) Head and Neck Cancer Patients Who Have Progressed After Chemotherapy

**Conditions:**
- Head and Neck Neoplasms
- Carcinoma, Squamous Cell
Interventions: Drug: Afatinib; Drug: Methotrexate

INEC Study: Immuno-modulating Enteral Nutrition in Cancer

Conditions: Malnutrition; Esophageal Cancer; Head and Neck Cancer

Interventions: Dietary Supplement: Impact (R) Enteral Nutrition; Other: impact

p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage

Condition: Malignant Tumors

Interventions: Drug: chemotherapy plus p53; Drug: chemotherapy; Radiation: radiotherapy

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Condition: Head and Neck Squamous Cell Carcinoma

Intervention: Procedure: Lymphoseek

Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer (Paradigm Trial)

Condition: Head and Neck Cancer

Interventions: Drug: carboplatin; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil; Radiation: radiation therapy

Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer

Conditions: Head and Neck Cancer; Xerostomia

Interventions: Drug: pilocarpine hydrochloride; Procedure: acupuncture-like transcutaneous electrical nerve
28  **Neurotropic Melanoma of the Head and Neck**

Condition:  Neurotropic Melanoma of the Head and Neck

Interventions:  Other: Observation;  Radiation: Radiation Therapy

29  **Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck**

Condition:  Skin Cancer

Interventions:  Drug: Carboplatin;  Radiation: Radiotherapy

30  **Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy**

Conditions:  Head and Neck Cancer;  Mucositis;  Oral Complications of Radiation Therapy;  Pain

Interventions:  Drug: doxepin hydrochloride;  Other: placebo

31  **Chemoradiotherapy HNSCC, Randomized Study, Docetaxel, Cisplatin, 5FU, Erbitux.**

Condition:  Squamous Cell Head and Neck Carcinoma

Interventions:  Drug: carboplatin;  Drug: 5 fluorouracil;  Radiation: radiation therapy

32  **Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux®**

Condition:  Head and Neck Carcinoma

Interventions:  Other: Radiotherapy + Erbitux® + placebo;  Other: Radiotherapy+Erbitux+OTD70DERM

33  **Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial**
**Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine**

**Conditions:** Oral Mucositis; Stomatitis

**Interventions:** Drug: Amifostine; Radiation: Amifostine

---

**Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence**

**Condition:** Head and Neck Cancer

**Interventions:** Biological: panitumumab; Drug: cisplatin; Drug: fluorouracil; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy

---

**Xerostomia Acupuncture Trial**

**Condition:** Head and Neck Cancer

**Interventions:** Procedure: True Acupuncture; Procedure: Sham Acupuncture; Other: Standard Care; Other: Questionnaire

---

**Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population**

**Conditions:** Pharynx Cancer; Larynx Cancer; Oral Cavity Cancer; Malignant Neoplasm of Esophagus
Intervention: Procedure: Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years

RTOG 0920: A Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-advanced Resected Head and Neck Cancer

Condition: Pathologically Confirmed SCC of the Head/Neck (Oral Cavity, Oropharynx or Larynx); Clinical Stage T2-3, N0-2, M0 or T1, N1-2, M0.

Interventions: Radiation: Radiation Therapy Alone; Radiation: Radiation Therapy + Cetuximab

Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin

Condition: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: docetaxel - cisplatin - 5-fluorouracil; Radiation: radiotherapy; Drug: cetuximab; Drug: cisplatin

A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery

Condition: Head and Neck Cancer

Interventions: Other: Flexible Fiber-based CO2 Laser, Quality of Life forms; Other: electrocautery resection and quality of life forms

Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.

Conditions: Oropharyngeal Cancer; Oral Cancer; Lymph Node
Metastasis

Intervention: Radiation: Radiation therapy

42 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors

Conditions: Head and Neck Cancer; Ototoxicity; Radiation Toxicity

Interventions: Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy

43 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx

Condition: Head and Neck Cancer

Interventions: Biological: aldesleukin; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: radiation therapy

44 Cisplatin and Radiation Therapy With or Without Gemcitabine Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced Nasopharyngeal Cancer

Condition: Head and Neck Cancer

Interventions: Drug: carboplatin; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: paclitaxel; Radiation: intensity-modulated radiation therapy

45 A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer

Conditions: Radiotherapy Induced Mucositis; Head and Neck Cancer

Interventions: Dietary Supplement: manuka honey; Dietary Supplement: placebo gel
46  **Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer**

**Conditions:**  Head and Neck Cancer; Precancerous Condition

**Interventions:**  Biological: cetuximab; Drug: cisplatin

47  **Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer**

**Conditions:**  Head and Neck Cancer; Radiation Toxicity

**Interventions:**  Drug: amifostine trihydrate; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy

48  **Do Selective Radiation Dose Escalation and Tumour Hypoxia Status Impact the Locoregional Tumour Control After Radiochemotherapy of Head & Neck Tumours?**

**Condition:**  Locally Advanced Head and Neck Cancer

**Intervention:**  Radiation: Radiotherapy with linear accelerators

49  **IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC**

**Conditions:**  Oral Cancer; Oropharynx Cancer; Hypopharynx Cancer

**Interventions:**  Procedure: IMRT 75 Gy; Procedure: Conventional radiotherapy 70 Gy; Drug: concomitant cisplatin

50  **Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer**

**Condition:**  Advanced Nasopharyngeal Cancer

**Interventions:**  Drug: Nimotuzumab; Drug: placebo plus chemoradiotherapy

51  **Effects of Mucoprotective Product on Xerostomia**

**Condition:**  Xerostomia

**Intervention:**  Other: XER2020
52 **Oral Cancer Adjuvant Therapy (OCAT) Trial**

**Condition:** Mouth Neoplasms

**Intervention:** Procedure: Post-operative chemoradiotherapy / accelerated radiotherapy

53 **Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer**

**Condition:** Head & Neck Carcinoma

**Interventions:** Drug: Nimotuzumab; Drug: Placebo

54 **Elective Versus Therapeutic Neck Dissection in the Treatment of Early Node Negative Squamous Carcinoma of the Oral Cavity**

**Condition:** Oral Cancer

**Intervention:** Procedure: Elective Vs Therapeutic neck dissection in early oral cancer

55 **Effectiveness of a Cognitive and Physical Intervention to Reduce Head and Muscle Pain in a Large Population**

**Conditions:** Migraine; Tension Type Headache; Cervical Pain

**Intervention:** Behavioral: Behavioral: Cognitive, Relaxation, Exercise Therapy

56 **Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux**

**Condition:** HNSCC

**Interventions:** Drug: cetuximab; Drug: Carboplatin, 5FU concomitant; Radiation: Radiotherapy

57 **Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma**

**Condition:** Thyroid Cancer
Intervention: Procedure: Prophylactic central lymph node dissection

58 Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment

Condition: Cisplatin Ototoxicity
Intervention: Drug: Dexamethasone Phosphate

59 Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques

Condition: Face Pain
Interventions: Drug: lidocaine; Drug: chemodenercation

60 Effect of Saliva Substitutes on Dental Hard Tissues in Situ

Condition: Hyposalivation
Interventions: Drug: Glandosane; Device: Saliva natura

61 Pharyngocise Dose Response Study

Condition: Dysphagia
Intervention: Behavioral: Pharyngocise

62 The Effect of Preoperative Oral Prednisone on the Operative Field During Nasal Polypectomy.

Condition: Nasal Polyps
Interventions: Drug: Prednisone; Drug: Placebo comparator

63 Efficacy and Safety Study of Leukocyte Interleukin, Injection (LI) to Treat Cancer of the Oral Cavity

Conditions: Squamous Cell Carcinoma (SCC) of the Oral Cavity; Squamous Cell Carcinoma of the Soft Palate
Interventions: Biological: LI plus CIZ; Other: Standard of Care (SOC); Biological: LI + SOC

64 Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Condition: Obstructive Sleep Apnea
Intervention: Device: Inspire Upper Airway Stimulator

65 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy
Conditions: Laryngopharyngeal Reflux; Hypertrophy of Lingual Tonsil
Intervention: Drug: dexlansoprazole

66 Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain
Conditions: Thyroid Carcinoma; Thyroidectomy
Intervention: Drug: Usage of Fibrin sealant

67 Three Field Radical Esophagectomy Versus Two Field Esophagectomy - a Prospective Trial
Condition: Cancer of Esophagus
Intervention: Procedure: Two field vs Three field lymphadenectomy

68 A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer
Condition: Esophageal Neoplasms
Intervention: Procedure: Esophagectomy

69 p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer
Condition: Esophageal Cancer
Interventions: Drug: 5-Fluoruracil, Cisplatinum; Drug: Docetaxel
70 Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Condition: Nasopharyngeal Carcinoma

Interventions: Radiation: Late-course accelerated hyperfractionated IMRT; Drug: Concomitant cisplatin chemotherapy; Radiation: Conventionally fractionated IMRT

71 Esophagectomy: Sweet Versus Ivor-Lewis

Condition: Esophageal Neoplasms

Intervention: Procedure: Esophagectomy

72 Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer

Interventions: Drug: Paclitaxel; Drug: Cisplatin; Drug: Tarceva; Radiation: Radiotherapy

73 Concurrent Chemoradiation Versus Surgery With Adjuvant Therapy in Advanced Laryngopharyngeal Cancers

Condition: Larynx Neoplasms

Interventions: Radiation: Concurrent Chemoradiation; Procedure: Laryngectomy + adjuvant radiotherapy/chemoradiotherapy

74 Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus

Condition: Esophageal Cancer

Interventions: Radiation: Conformal 3D Radiotherapy with " ENI "-type prophylactic irradiation of the lymph node; Radiation: Boost; Drug: chemotherapy: FOLF
75 Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer

Condition: Thyroid Cancer

Intervention: Drug: Thyrogen combined with continuing Liothyronine treatment

76 rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors

Condition: Advanced Malignant Thyroid Tumors


77 Improve the Treatment of Thoracic Esophageal Cancer

Condition: Thoracic Esophageal Squamous Cell Carcinoma

Interventions: Drug: adjuvant chemotherapy; Procedure: standard two field Lymphadenectomy; Procedure: Total two field Lymphadenectomy; Procedure: three field Lymphadenectomy

78 A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Condition: Nasopharyngeal Carcinoma

Intervention: Drug: neoadjuvant chemotherapy plus concurrent chemoradiotherapy

79 A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Squamous Cell Esophageal Carcinoma

Condition: Squamous Cell Esophageal Carcinoma

Interventions: Procedure: Neo-adjuvant Chemoradiotherapy followed by Surgery; Procedure: surgery
80  Elastography Interest in the Management of Thyroid Nodules

Condition: Thyroid Nodules

Intervention: Device: Medical ultrasound device (ShearWave system)

81  123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

Conditions: Pheochromocytoma; Neuroblastoma; Paraganglioma; Medullary Thyroid Carcinoma; Carcinoid Tumors

Intervention: Drug: 123I-meta-iodobenzylguanidine

82  Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer

Interventions: Biological: cetuximab; Drug: cisplatin; Drug: docetaxel; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: radiation therapy

83  Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial

Condition: Esophageal Neoplasms

Interventions: Other: Preoperative treatment of chemotherapy and radiation; Other: Postoperative treatment of chemotherapy and radiation

84  The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy

Condition: Oesophageal Cancer

Intervention: Procedure: gastric tube
85  A Study of Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer

Conditions:  Esophageal Cancer; Adenocarcinoma

Interventions:  Drug: Nimotuzumab; Drug: Cisplatin; Drug: Fluorouracil; Radiation: Radiotherapy

86  Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer

Conditions:  Esophageal Cancer; Stomach Cancer

Intervention:  Drug: Pravastatin

87  A Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer

Condition:  Thyroid Cancer

Interventions:  Drug: E7080 24 mg administered orally, once a day;
Drug: Placebo 24mg administered orally, once a day

88  Open Versus Laparoscopically-assisted Esophagectomy for Cancer

Condition:  Esophageal Cancer

Intervention:  Procedure: esophagectomy with extended two-field lymphadenectomy

89  Neoadjuvant Chemo vs Chemorad Esophageal Cancer

Conditions:  Esophageal Cancer; Adenocarcinoma, Esophageal; Squamous Cell Carcinoma, Esophageal; Carcinoma, Gastroesophageal Junction

Interventions:  Drug: carboplatin and paclitaxel; Other: Carboplatin paclitaxel plus concurrent radiotherapy

90  Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Condition:  Nasopharyngeal Carcinoma
Interventions: Drug: Docetaxel, cisplatin and fluorouracil; Drug: Cisplatin

91 Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma

Condition: Nasopharyngeal Carcinoma

Interventions: Drug: Capecitabine; Drug: Adjuvant chemotherapy using PF (5-Fluorouracil); Drug: Induction chemotherapy using PF (5-Fluorouracil)

92 Study of CryoSpray Ablation(TM) to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.

Conditions: Barrett’s Esophagus; Esophageal Cancer

Intervention: Device: CryoSpray Ablation(TM)

93 Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer

Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy

94 Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection

Condition: Esophageal Cancer

Intervention: Other: fluid optimisation

95 Erlotinib Prevention of Oral Cancer (EPOC)

Condition: Oral Cancer

Interventions: Drug: Erlotinib; Drug: Placebo
96 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy

Condition: Esophageal Squamous Cell Carcinoma

Interventions: Biological: Nimotuzumab; Radiation: Radiation therapy; Radiation: radiation therapy; Drug: chemotherapy

97 Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia.

Condition: Esophagus Cancer

Interventions: Drug: Cisplatin; Radiation: Radiation therapy; Drug: 5-Fluorouracil

98 Esomeprazole With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett's Metaplasia

Conditions: Esophageal Cancer; Precancerous Condition

Interventions: Drug: acetylsalicylic acid; Drug: esomeprazole magnesium; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: immunohistoc hemistry staining method; Procedure: biopsy

99 Esophagectomy Associated Respiratory Complications: Ivor-Lewis Versus Sweet Approaches

Conditions: Esophageal Cancer; Postoperative Complications; Diaphragm; Pulmonary Function

Interventions: Procedure: Ivor-Lewis Esophagectomy; Procedure: Sweet Esophagectomy

100 Endoesophageal Cryotherapy For Ablating Barrett’s Esophagus and Early Stage Esophageal Cancer
Condition: Barrett’s Esophagus

Procedure: Endoscopic spray cryotherapy

IX. PubMed Search in HNSCC

Search = HNSCC OR "head and neck cancer", published in the last 180 days, English only

Randomized Controlled Trials

Results: 1

1. Radiofrequency ablation of advanced head and neck cancer.


PMID:
21576561

[PubMed - indexed for MEDLINE]

Related citations

Reviews

Results: 1 to 20 of 21

1. ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck.

Expert Panel on Radiation Oncology-Head and Neck, Salama JK, Saba N, Quon H, Garg MK, Lawson J, McDonald MW, Ridge JA, Smith RV, Yeung AR, Yom SS, Beitler JJ.
2. Delineating neck targets for intensity-modulated radiation therapy of head and neck cancer.

David MB, Eisbruch A.


PMID:
21625157

[PubMed - indexed for MEDLINE]

Related citations

3. Nutrition management of patients with malignancies of the head and neck.

O'Neill JP, Shaha AR.


PMID:
21621700

[PubMed - indexed for MEDLINE]

Related citations

4. (18)FDG-PET/CT for detecting distant metastases and second primary cancers in patients with head and neck cancer. A meta-analysis.

PMID:
21621450

[PubMed - indexed for MEDLINE]

Related citations

5.

Head and neck cancer as a model for advances in imaging prognosis, early assessment, and posttherapy evaluation.


PMID:
21610469

[PubMed - indexed for MEDLINE]

Related citations

6.

Advances in imaging: target delineation.


PMID:
21610467

[PubMed - indexed for MEDLINE]

Related citations

7.
A miR-centric view of head and neck cancers.

Babu JM, Prathibha R, Jijith VS, Hariharan R, Pillai MR.


PMID: 21549178

[PubMed - indexed for MEDLINE]

Related citations

8. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer.


PMID: 21530100

[PubMed - indexed for MEDLINE]

Related citations


PMID: 21518651

[PubMed - indexed for MEDLINE]

Related citations
10. Mammalian target of rapamycin and head and neck squamous cell carcinoma.
Liao YM, Kim C, Yen Y.
PMID: 21513566
[PubMed - indexed for MEDLINE]
Free PMC Article
Free full text Related citations

Cheng SC, Wu VW, Kwong DL, Ying MT.
Br J Radiol. 2011 May;84(1001):393-402. Review.
PMID: 21511748
[PubMed - indexed for MEDLINE]
Related citations

Brait M, Sidransky D.
PMID: 21495866
[PubMed - indexed for MEDLINE]
Related citations

13. Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data.
Reeves TD, Hill EG, Armeson KE, Gillespie MB.
PMID: 21493327
[PubMed - indexed for MEDLINE]

Related citations

14. Dental implants in oral cancer reconstruction.
Kim DD, Ghali GE.
PMID: 21492805
[PubMed - indexed for MEDLINE]

Related citations

Furness S, Glenny AM, Worthington HV, Pavitt S, Oliver R, Clarkson JE, Macluskey M, Chan KK, Conway DI.
PMID: 21491393
Bensadoun RJ, Patton LL, Lalla RV, Epstein JB.
PMID: 21479787

17. Feasibility of Tomotherapy to spare the cochlea from excessive radiation in head and neck cancer.
PMID: 21474364

Wilson JC, Anderson LA, Murray LJ, Hughes CM.
PMID:
Role of molecular markers in the management of head and neck cancers.

Ferreira MB, De Souza JA, Cohen EE.

Curr Opin Oncol. 2011 May;23(3):259-64. Review.

PMID:
21358329

[PubMed - indexed for MEDLINE]

Related citations

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.

Brand TM, Iida M, Wheeler DL.


PMID:
21293176

[PubMed - indexed for MEDLINE]

Related citations

Editorials

Results: 2

Uroporphyrinogen decarboxylase: optimizing radiotherapy for head and neck cancer.
Ito E, Yip KW, Liu FF.


**PMID:**

21568673

[PubMed - in process]

*Free Article*

*Related citations*

□ 2.

*Is narrow band imaging the ideal screening tool for mucosal head and neck cancer?*

Piazza C.


**PMID:**

21421337

[PubMed - indexed for MEDLINE]

*Related citations*